Rosemarie Mick

TL;DR: Major tumour regressions are reported in a subset of patients with metastatic melanoma treated with an anti-CTLA4 antibody and radiation and reproduced this effect in mouse models, showing that PD-L1 on melanoma cells allows tumours to escape anti- NCTLA4-based therapy, and the combination of radiation, anti- CTLA4 and anti-PD-L 1 promotes response and immunity through distinct mechanisms.

TL;DR: Blood profiling of peripheral blood from patients with stage IV melanoma before and after treatment with the PD-1-targeting antibody pembrolizumab is used to identify pharmacodynamic changes in circulating exhausted-phenotype CD8 T cells (Tex cells) and identify a clinically accessible potential on-treatment predictor of response to PD- 1 blockade.

TL;DR: The findings suggest that productive tumor immunity may be undermined from the start, and efforts to test potent inhibitors of MDSC, tumor-associated macrophages, and Treg, particularly early in the disease represent important next steps for developing novel immunotherapy of cancer.

TL;DR: Modulation of glucuronidation may be effective in increasing the therapeutic index of CPT-11, and the relatively higher index values, suggestive of higher biliary concentrations of SN-38, were possibly due to low glucuronidated rates.

TL;DR: Increases in liver stiffness precede fibrosis and potentially myofibroblast activation, and it is suggested that increased liver stiffness may play an important role in initiating the early stages of fibrosis.